Published on
August 17, 2026
- 12:00 GMT
Mandara Biopharma Launches Their Phase 2/3 Clinical Trial for Alzheimer’s Agitation
Mandara Biopharma Inc. officially launched their Phase 2/3 clinical trial in Australia for the treatment of agitation associated with Alzheimer’s disease. BOULDER, CO, UNITED STATES, August 17, 2026 /EINPresswire.com/ -- Mandara Biopharma Inc., a …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
